MDLinx: The Role of Bloodwork in Peptide Therapy
MDLinx recently featured insights from Sean Arora, MD, CEO and Co-Founder of Arora Health, on the growing demand for comprehensive bloodwork among patients exploring peptide therapy and the importance of individualized clinical evaluations.
As interest in peptides for longevity, recovery, and metabolic health grows, physicians are encountering more patients requesting extensive laboratory testing, sometimes before beginning therapies they discovered through online wellness communities or social media. In the article, "‘Can you just check everything?’ The hidden peptide question behind the ‘full bloodwork’ request," Dr. Arora joins other medical experts in discussing how clinicians can navigate these requests, identify potential risks, and make informed testing decisions based on each patient's medical history and treatment goals.
Article highlights
The MDLinx feature explores several key themes, including:
- Recognizing the growing interest in peptide therapy. Patients are increasingly exploring peptides for weight management, recovery, and longevity, often influenced by online communities and wellness trends. This growing interest is changing the types of questions and laboratory requests physicians encounter.
- Understanding the limitations of comprehensive bloodwork. Ordering extensive laboratory panels without a clear clinical purpose can introduce unnecessary costs, incidental findings, and false-positive results that complicate patient care.
- Prioritizing individualized laboratory testing. Appropriate bloodwork should be guided by medical history, metabolic risk factors, symptoms, and the specific therapy being considered rather than a standardized approach for every patient.
- Identifying potential risks associated with experimental peptides. Many emerging peptides lack sufficient human safety and efficacy data, while products obtained through unregulated sources may introduce additional concerns related to quality, purity, and dosing.
- Encouraging open conversations about peptide use. Patients may not always disclose therapies they are considering or already using. Understanding their motivations can help physicians identify potential risks and recommend appropriate evaluations.
- Supporting coordinated, multidisciplinary care. Collaboration among prescribing physicians, nutrition professionals, and other healthcare providers can help ensure that laboratory testing and treatment decisions reflect each patient's broader health needs.
Taking a more personalized approach to laboratory testing
Dr. Arora emphasizes that laboratory testing should serve a specific clinical purpose rather than simply provide patients with the largest possible collection of results.
"The honest answer is that targeted labs are appropriate when they answer a specific clinical question or establish a genuine baseline for a therapy with metabolic implications, like GLP-1 or peptides affecting body composition or metabolic function."
He also highlights the value of a multidisciplinary approach, explaining that appropriate testing can vary considerably depending on a patient's medical history, metabolic risks, and therapeutic goals.
As peptide therapy attracts greater attention, healthcare providers face an important responsibility to help patients distinguish emerging research from established clinical evidence. Thoughtful patient evaluations, targeted laboratory testing, and open communication can help clinicians navigate these conversations while maintaining high standards of patient safety.
Build what's next on a stronger clinical foundation.
Whether you're launching a new clinical program, expanding a clinic, entering new markets, or scaling a digital health platform, Arora helps you build the physician-led clinical and compliance infrastructure to do it responsibly.